New hope for diabetic eye disease: experimental drug SNP318 enters Mid-Stage trial
NCT ID NCT07199777
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called SNP318 in 60 people with diabetic macular edema, a condition that causes vision loss due to swelling in the retina. Participants will receive either the drug or a placebo, and researchers will monitor safety, eye thickness, and vision changes over time. The goal is to see if SNP318 can help control the disease and improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.